COMPULSORY LICENSING AS A TOOL FOR GLOBAL PUBLIC INTEREST: EVOLUTION, CHALLENGES, AND REFORM
##semicolon##
Compulsory Licensing; TRIPS Agreement; Doha Declaration; Intellectual Property; Public Health; Access to Medicines; Sustainable Development; Innovation Equity; Green Technologies; Digital Access; Food Security; WTO; WIPO.##article.abstract##
This paper explores the evolving role of compulsory licensing (CL) as a critical
legal and policy tool for reconciling intellectual property rights with the broader public
interest in the 21st century. While the TRIPS Agreement and the Doha Declaration
provide member states with considerable flexibility to issue CLs in situations of
national emergency and public need, practical obstacles—including procedural
complexity, vague legal definitions, and geopolitical pressures—continue to limit its
application. Drawing on historical development, international legal frameworks, and
recent case studies, this study examines the potential of CL not only in the context of
public health, but also in addressing global challenges such as climate change, digital
inequality, and food insecurity. The conclusion outlines specific legal, institutional,
and policy reforms at national and international levels aimed at making CL more
effective, equitable, and responsive to emerging societal needs. By reframing CL as a
mechanism of innovation equity, the paper argues for a renewed commitment to
cooperative global governance in the management and dissemination of patented
knowledge.
##submission.citations##
1.
Abbott, F.M., 2005. The WTO medicines decision: world pharmaceutical trade
and the protection of public health. American Journal of International Law, 99(2),
pp.317–358.
2.
Correa, C.M., 2002. Implications of the Doha Declaration on the TRIPS
Agreement and Public Health. Geneva: World Health Organization.
3.
Kienzle, B., 2014. Compulsory licensing in the pharmaceutical sector: a global
perspective of the tension between IP rights and public health needs. Journal of
Intellectual Property Law & Practice, 9(12), pp.1011–1020.
4.
Love, J., 2007. Remuneration Guidelines for Non-Voluntary Use of a Patent on
Medical Technologies. Geneva: World Health Organization/UNDP.
5.
UNCTAD. (2022). Compulsory licensing practices and policies: Global
overview. [Electronic resource]. Retrieved from https://unctad.org
6.
World Health Organization (WHO). (2021). COVID-19 Technology Access
Pool (C-TAP). Geneva: WHO.
7.
Pugach, M. P. (2021). Compulsory licensing in the pandemic era: policy shifts
and global implications. Innovation Files;
8.
President of the Republic of Uzbekistan. (2022, April 26). On additional
measures for the further development of the field of intellectual property, Decree No.
PP–221. [Electronic resource]. Retrieved from https://lex.uz/docs/5987120
